Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • AFT Pharmaceuticals are travelling towards a clinical trial of its drug ‘Pascomer’ after settling a deal with dermatology drug developers Timber
  • Pascomer is a skincare drug for treating Tuberous Sclerosis – a disease said to affect over 30,000 people in the U.S.
  • Timber will be paying for clinical trials of Pascomer for a planned 120 patients in eight study centres across the U.S., Canada and Mexico
  • AFT claims if the trials are successful, treating Tuberous Sclerosis patients could be an industry worth over US$300 million

Distributor and marketing company AFT Pharmaceuticals has secured a licensing and clinical deal for its skincare drug, Pascomer.

Inked with dermatology drug developers Timber, Pascomer will be reaching test patients in the U.S., Canada and Mexico. Pascomer is applied to the face of Tuberous Sclerosis patients – a disease said to affect over 30,000 people in the U.S.

AFT management claims that if clinical studies for Pascomer and its treatment are successful, helping Tuberous Sclerosis patients would be an industry worth over US$300 million.

Clinical studies for Pascomer are planned for 120 patients across eight study centres. Additional research centres in Australia, Spain, the U.K. and New Zealand will also take part. Full results are expected in 2020.

“The deal we have struck with Timber, mitigates AFT’s research and development risks, while still promising strong returns for the company if the clinical trials proceed successfully,” said AFT CEO Dr Hartley Atkinson.

AFT will receive milestone payments of US$10 million from Timber as clinical studies proceed successfully. However, AFT says its profit guidance for the 2020 financial year will remain unchanged, staying between NZ$9-12 million.

“Facial angiofibromas are a disfiguring condition affecting patients from childhood. So, a successful Pascomer development will offer an important therapeutic option to these sufferers,” said Hartley.

Pre-clinical development work has been completed for planning the upcoming trials – alongside approvals from the FDA. Timber will cover costs for the trial and payment of AFT’s staff.

“AFT’s dermal delivery technology coupled with Pascomer is potentially a significant breakthrough for people with facial angiofibromas,” added Timber President Zach Rome in this morning’s ASX announcement.

Shares in AFP are untouched today, stagnant at $2.91 a share. The company’s market cap is valued at $283.1 million.

AFP by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.